Monitoring glucose levels is critical for effective diabetes management. Continuous glucose monitoring devices estimate interstitial glucose levels and provide alerts for glycemic excursions. However, they are expensive and invasive. Therefore, low-cost, noninvasive alternatives are useful for patients with diabetes. In this article, we explore electrocardiogram signals as a potential alternative to detecting glycemic excursions by extracting intrabeat (beat-morphology) and inter-beat (heart rate variability) information. Unlike prior methods that focused only on the standard clinical excursion thresholds (70 mg/dL for hypoglycemia, 180 mg/dL for hyperglycemia), our proposed approach trains independent machine learning models at various excursion thresholds, aggregating their outputs for a final prediction. This allows learning morphological patterns in the neighborhood of the standard excursion thresholds. Our personalized fusion models achieve an AUC of 75 % for hypoglycemia and 78% for hyperglycemia detection across patients, resulting in an average improvement of 4 % compared to the baseline models (trained using only standard clinical thresholds) for detecting glycemic excursions. We also find that combining morphology and HRV information outperforms using them individually (5 % for hypoglycemia and 6 % for hyperglycemia). The data used in this article was collected from 12 patients with type-1 diabetes, each monitored over a 14-day period at Texas Children’s Hospital, Houston. The results indicate that a combination of morphological and HRV features is essential for noninvasive detection of glycemic excursions. Also, morphological changes can happen at varying glucose levels for different patients and capturing these changes provide valuable information that leads to improved prediction performance for detecting glycemic excursions.
more »
« less
Detection of Hypoglycemia and Hyperglycemia Using Noninvasive Wearable Sensors: ECG and Accelerometry
Background: Monitoring glucose excursions is important in diabetes management. This can be achieved using continuous glucose monitors (CGMs). However, CGMs are expensive and invasive. Thus, alternative low-cost noninvasive wearable sensors capable of predicting glycemic excursions could be a game changer to manage diabetes. Methods: In this article, we explore two noninvasive sensor modalities, electrocardiograms (ECGs) and accelerometers, collected on five healthy participants over two weeks, to predict both hypoglycemic and hyperglycemic excursions. We extract 29 features encompassing heart rate variability features from the ECG, and time- and frequency-domain features from the accelerometer. We evaluated two machine-learning approaches to predict glycemic excursions: a classification model and a regression model. Results: The best model for both hypoglycemia and hyperglycemia detection was the regression model based on ECG and accelerometer data, yielding 76% sensitivity and specificity for hypoglycemia and 79% sensitivity and specificity for hyperglycemia. This had an improvement of 5% in sensitivity and specificity for both hypoglycemia and hyperglycemia when compared with using ECG data alone. Conclusions: Electrocardiogram is a promising alternative not only to detect hypoglycemia but also to predict hyperglycemia. Supplementing ECG data with contextual information from accelerometer data can improve glucose prediction.
more »
« less
- Award ID(s):
- 2037383
- PAR ID:
- 10352256
- Date Published:
- Journal Name:
- Journal of Diabetes Science and Technology
- ISSN:
- 1932-2968
- Page Range / eLocation ID:
- 193229682211163
- Format(s):
- Medium: X
- Sponsoring Org:
- National Science Foundation
More Like this
-
-
Abstract BackgroundEffective diabetes management requires precise glycemic control to prevent both hypoglycemia and hyperglycemia, yet existing machine learning (ML) and reinforcement learning (RL) approaches often fail to balance competing objectives. Traditional RL-based glucose regulation systems primarily focus on single-objective optimization, overlooking factors such as minimizing insulin overuse, reducing glycemic variability, and ensuring patient safety. Furthermore, these approaches typically rely on centralized data processing, which raises privacy concerns due to the sensitive nature of health care data. There is a critical need for a decentralized, privacy-preserving framework that can personalize blood glucose regulation while addressing the multiobjective nature of diabetes management. ObjectiveThis study aimed to develop and validate PRIMO-FRL (Privacy-Preserving Reinforcement Learning for Individualized Multi-Objective Glycemic Management Using Federated Reinforcement Learning), a novel framework that optimizes clinical objectives—maximizing time in range (TIR), reducing hypoglycemia and hyperglycemia, and minimizing glycemic risk—while preserving patient privacy. MethodsWe developed PRIMO-FRL, integrating multiobjective reward shaping to dynamically balance glucose stability, insulin efficiency, and risk reduction. The model was trained and tested using simulated data from 30 simulated patients (10 children, 10 adolescents, and 10 adults) generated with the Food and Drug Administration (FDA)–approved UVA/Padova simulator. A comparative analysis was conducted against state-of-the-art RL and ML models, evaluating performance using metrics such as TIR, hypoglycemia (<70 mg/dL), hyperglycemia (>180 mg/dL), and glycemic risk scores. ResultsThe PRIMO-FRL model achieved a robust overall TIR of 76.54%, with adults demonstrating the highest TIR at 81.48%, followed by children at 77.78% and adolescents at 70.37%. Importantly, the approach eliminated hypoglycemia, with 0.0% spent below 70 mg/dL across all cohorts, significantly outperforming existing methods. Mild hyperglycemia (180-250 mg/dL) was observed in adolescents (29.63%), children (22.22%), and adults (18.52%), with adults exhibiting the best control. Furthermore, the PRIMO-FRL approach consistently reduced glycemic risk scores, demonstrating improved safety and long-term stability in glucose regulation.. ConclusionsOur findings highlight the potential of PRIMO-FRL as a transformative, privacy-preserving approach to personalized glycemic management. By integrating federated RL, this framework eliminates hypoglycemia, improves TIR, and preserves data privacy by decentralizing model training. Unlike traditional centralized approaches that require sharing sensitive health data, PRIMO-FRL leverages federated learning to keep patient data local, significantly reducing privacy risks while enabling adaptive and personalized glucose control. This multiobjective optimization strategy offers a scalable, secure, and clinically viable solution for real-world diabetes care. The ability to train personalized models across diverse populations without exposing raw data makes PRIMO-FRL well-suited for deployment in privacy-sensitive health care environments. These results pave the way for future clinical adoption, demonstrating the potential of privacy-preserving artificial intelligence in optimizing glycemic regulation while maintaining security, adaptability, and personalization.more » « less
-
In this paper, we provide an approach to data-driven control for artificial pancreas systems by learning neural network models of human insulin-glucose physiology from available patient data and using a mixed integer optimization approach to control blood glucose levels in real-time using the inferred models. First, our approach learns neural networks to predict the future blood glucose values from given data on insulin infusion and their resulting effects on blood glucose levels. However, to provide guarantees on the resulting model, we use quantile regression to fit multiple neural networks that predict upper and lower quantiles of the future blood glucose levels, in addition to the mean. Using the inferred set of neural networks, we formulate a model-predictive control scheme that adjusts both basal and bolus insulin delivery to ensure that the risk of harmful hypoglycemia and hyperglycemia are bounded using the quantile models while the mean prediction stays as close as possible to the desired target. We discuss how this scheme can handle disturbances from large unannounced meals as well as infeasibilities that result from situations where the uncertainties in future glucose predictions are too high. We experimentally evaluate this approach on data obtained from a set of 17 patients over a course of 40 nights per patient. Furthermore, we also test our approach using neural networks obtained from virtual patient models available through the UVA-Padova simulator for type-1 diabetes.more » « less
-
OBJECTIVETo determine the benefit of starting continuous glucose monitoring (CGM) in adult-onset type 1 diabetes (T1D) and type 2 diabetes (T2D) with regard to longer-term glucose control and serious clinical events. RESEARCH DESIGN AND METHODSA retrospective observational cohort study within the Veterans Affairs Health Care System was used to compare glucose control and hypoglycemia- or hyperglycemia-related admission to an emergency room or hospital and all-cause hospitalization between propensity score overlap weighted initiators of CGM and nonusers over 12 months. RESULTSCGM users receiving insulin (n = 5,015 with T1D and n = 15,706 with T2D) and similar numbers of nonusers were identified from 1 January 2015 to 31 December 2020. Declines in HbA1c were significantly greater in CGM users with T1D (−0.26%; 95% CI −0.33, −0.19%) and T2D (−0.35%; 95% CI −0.40, −0.31%) than in nonusers at 12 months. Percentages of patients achieving HbA1c <8 and <9% after 12 months were greater in CGM users. In T1D, CGM initiation was associated with significantly reduced risk of hypoglycemia (hazard ratio [HR] 0.69; 95% CI 0.48, 0.98) and all-cause hospitalization (HR 0.75; 95% CI 0.63, 0.90). In patients with T2D, there was a reduction in risk of hyperglycemia in CGM users (HR 0.87; 95% CI 0.77, 0.99) and all-cause hospitalization (HR 0.89; 95% CI 0.83, 0.97). Several subgroups (based on baseline age, HbA1c, hypoglycemic risk, or follow-up CGM use) had even greater responses. CONCLUSIONSIn a large national cohort, initiation of CGM was associated with sustained improvement in HbA1c in patients with later-onset T1D and patients with T2D using insulin. This was accompanied by a clear pattern of reduced risk of admission to an emergency room or hospital for hypoglycemia or hyperglycemia and of all-cause hospitalization.more » « less
-
Background:Achieving optimal glycemic control for persons with diabetes remains difficult. Real-world continuous glucose monitoring (CGM) data can illuminate previously underrecognized glycemic fluctuations. We aimed to characterize glucose trajectories in individuals with Type 1 and Type 2 diabetes, and to examine how baseline glycemic control, CGM usage frequency, and regional differences shape these patterns. Methods:We linked Dexcom CGM data (2015–2020) with Veterans Health Administration electronic health records, identifying 892 Type 1 and 1716 Type 2 diabetes patients. Analyses focused on the first three years of CGM use, encompassing over 2.1 million glucose readings. We explored temporal trends in average daily glucose and time-in-range values. Results:Both Type 1 and Type 2 cohorts exhibited a gradual rise in mean daily glucose over time, although higher CGM usage frequency was associated with lower overall glucose or attenuated increases. Notable weekly patterns emerged: Sundays consistently showed the highest glucose values, whereas Wednesdays tended to have the lowest. Seasonally, glycemic control deteriorated from October to February and rebounded from April to August, with more pronounced fluctuations in the Northeast compared to the Southwest U.S. Conclusions:Our findings underscore the importance of recognizing day-of-week and seasonal glycemic variations in diabetes management. Tailoring interventions to account for these real-world fluctuations may enhance patient engagement, optimize glycemic control, and ultimately improve health outcomes.more » « less
An official website of the United States government

